Skip to main content

Tretten FDA Approval History

Last updated by Judith Stewart, BPharm on June 22, 2020.

FDA Approved: Yes (First approved December 23, 2013)
Brand name: Tretten
Generic name: coagulation factor XIII A-subunit (recombinant)
Company: Novo Nordisk
Treatment for: Factor XIII A-Subunit Deficiency

Tretten (coagulation factor XIII A-subunit (recombinant)) is a recombinant analogue of the human Factor XIII A-subunit for the prevention of bleeding in patients who have the rare clotting disorder congenital Factor XIII A-subunit deficiency.

Development timeline for Tretten

Dec 23, 2013Approval FDA Approves Tretten to Treat Rare Genetic Clotting Disorder

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.